In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant Strains

✍ Scribed by Rybak, M. J.; Hershberger, E.; Moldovan, T.; Grucz, R. G.

• Book ID: 121345370
• Publisher: American Society for Microbiology
• Year: 2000
• Tongue: English
• Weight: 173 KB
• Volume: 44
• Category: Article
• ISSN: 0066-4804
• DOI: 10.1128/AAC.44.4.1062-1066.2000

✦ Synopsis

ABSTRACT

The in vitro activity of daptomycin was compared with those of vancomycin, linezolid, and quinupristin-dalfopristin against a variety (
n
= 203) of gram-positive bacteria, including methicillin-resistant
Staphylococcus aureus
and
S. epidermidis
(MRSA and MRSE, respectively), vancomycin-resistant enterococci (VRE), and vancomycin-intermediate
S. aureus
(VISA). Overall, daptomycin was more active against all organisms tested, except
Enterococcus faecium
and VISA, against which its activity was similar to that of quinupristin-dalfopristin. In time-kill studies with MRSA, MRSE, VRE, and VISA, daptomycin demonstrated greater bactericidal activity than all other drugs tested, killing ≥3 log CFU/ml by 8 h. Daptomycin may be a potential alternative drug therapy for multidrug-resistant gram-positive organisms and warrants further investigation.